DYNAMIC WEALTH RESEARCH
  • Stocks
  • Hard Assets
  • Cannabis
  • Tech
  • Biotech Stocks
  • About Us
  • Contact
  • News
  • Special Report
  •  
  •  
  •  

Psychedelic Stocks

 Psychedelic Stocks Home

MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA and LSD

MindMed begins the first Phase 1 clinical trial testing the safety and tolerance of MDMA and LSD in combination.

01/20/2021 PSW Editor

Entheon Biomedical Partners with Divergence Neuro Technologies Inc. for Predictive Biomarker Platform Development

Entheon announces a new partnership to advance its psychedelic drug R&D.

01/19/2021 PSW Editor

CYBIN Announces Upsize to Previously Announced Bought Deal Offering

Cybin's bought deal financing has been upsized to CAD$30 million.

01/19/2021 PSW Editor

Low Tide For Psychedelic Stocks With Media, Investors Distracted

The U.S. election has become a major political circus. With investors distracted and the media focused elsewhere, psychedelic stocks are temporarily at low tide.

01/19/2021 Jeff Nielson

Cybin Announces CDN$20 Million Bought Deal Offering

Cybin Corp announces a CAD$20 million financing at a unit price of CAD$2.25.

01/18/2021 PSW Editor

Entheon Biomedical Corp. Announces Acquisition of HaluGen Life Sciences Inc.

Entheon acquires a genetic screening company to identify genetic markers that affect reactions to hallucinogenic drugs.

01/14/2021 PSW Editor

Mydecine Innovations Group Upsizes Previously Announced Bought Deal

Mydecine's bought-deal financing is upsized by 50% to CAD $15 million.

01/14/2021 PSW Editor

MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience

MindMed's new Chief Development Officer has over a decade of experience leading drug development programs.

01/14/2021 PSW Editor

Mydecine Innovations Group Announces C$10 Million Bought Deal Offering of Units

Mydecine announces a bought-deal financing with units priced at CAD$0.50.

01/14/2021 Jeff Nielson

Novamind Expands Psychedelic Medicine Access in Utah

Novamind Inc announces the expansion and optimization of its Cedar Psychiatry clinic in Utah.

01/13/2021 PSW Editor

Core One Labs Announces Breakthrough in Solving Psilocybin Dosing Problems by Introducing Biosynthetic Psilocybin to its Patented Thinstrip Delivery Method

Core One Labs announces a research breakthrough to help improve consistency in psilocybin dosing.

01/12/2021 PSW Editor

Cybin Announces API Synthesis of Multiple Tryptamine Derivatives Based on the First Milestone Achievement Pursuant to the Adelia Acquisition

Cybin announces the API synthesis of multiple tryptamine derivatives.

01/12/2021 PSW Editor
  • 1
  • 2
  • 3
  • 4
  • ...
  • 26
  • Next

Exclusives

Responsive image
Joe Rogan And Tim Ferriss Drive Attention To Benefits Of Psychedelics

Two of the most powerful voices in new media are advocating for the mental health benefits of psychedelics in a big way.


Capital, Compounds and Clinics: Why 2021 Will Be A Stellar Year For Psychedelic Stocks

Prominent Bitcoin Investor’s Next Monster Bet

The Hottest Biotech In 2021

How Psychedelic Drug Stocks Took Off in 2020

Psychedelic Stocks Pump Up The Volume

SHARE DYNAMIC WEALTH RESEARCH

Our Mission

Learn More


  • About
  • Contact

Contact Us


info@dynamicwealthresearch.org
2010 West Avenue K #623
Lancaster, CA 93536

Subscribe to Newsletter

Stay informed on new causes and upcoming organization updates. Don't miss things!

By providing your e-mail, you are consenting to receive press releases and other information concerning Psychedelic Stock Watch and its affiliates and partners. You may withdraw your consent at any time.

UNSUBSCRIBE
© 2016 - 2021 DYNAMIC WEALTH RESEARCH, Privacy Policy, Disclaimer
powered by structure cms™